Danone workers rally against factory closure in Parets del Vallès
French multinational plans to relocate production to Valencia, with 157 jobs at stake
parets del vallès
Catalan pharmaceutical giant Grifols sees a 23% jump in net profit in the first half of 2014
During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.
Grifols strengthens its presence in the Chinese market
The Catalan pharmaceutical company Grífols, third worldwide company in plasma derivatives, has signed a cooperation agreement with the Shanghai Blood Bank. The agreement, which strengthens the presence of the Catalan company in China, promotes blood genotyping research. The Chinese institution will use the Grifols’ genetic test BLOODchip in transfusion compatibility studies. Shanghai Blood Bank serves over 20 million people and receives more than 300.000 donations per year. In 2011, Grifols sales in China grew by 30%.
Biochemical Grifols to double its plasma production capacity and to build a new plant in the U.S.
The Catalan pharmaceutical and chemical company was identified in a Wikileaks cable from the U.S. State Department as one of three strategic items the United States had in Spain, together with the natural gas pipeline from Algeria and the Gibraltar Strait. Grifols leads the blood plasma-based products’ market in Europe and is expanding its U.S. presence.